TR199902192T2 - Anti-CDL40 bilesiklerinin tedavi amaçli uygulama yöntemleri - Google Patents

Anti-CDL40 bilesiklerinin tedavi amaçli uygulama yöntemleri

Info

Publication number
TR199902192T2
TR199902192T2 TR1999/02192T TR9902192T TR199902192T2 TR 199902192 T2 TR199902192 T2 TR 199902192T2 TR 1999/02192 T TR1999/02192 T TR 1999/02192T TR 9902192 T TR9902192 T TR 9902192T TR 199902192 T2 TR199902192 T2 TR 199902192T2
Authority
TR
Turkey
Prior art keywords
compounds
cdl40
therapeutic administration
administration methods
methods
Prior art date
Application number
TR1999/02192T
Other languages
English (en)
Inventor
L.Kalled Susan
W. Thomas David
Original Assignee
Biogen,Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen,Inc filed Critical Biogen,Inc
Publication of TR199902192T2 publication Critical patent/TR199902192T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Bagisiklikla ilgili bozukluklar üç hafta veya daha fazla aralikla anti-CD40L bilesiklerinin uygulanmasi ile etkili bir sekilde tedavi edilebilir.
TR1999/02192T 1997-01-10 1998-01-09 Anti-CDL40 bilesiklerinin tedavi amaçli uygulama yöntemleri TR199902192T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3467297P 1997-01-10 1997-01-10
US4015497P 1997-03-07 1997-03-07

Publications (1)

Publication Number Publication Date
TR199902192T2 true TR199902192T2 (tr) 1999-12-21

Family

ID=26711241

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1999/02192T TR199902192T2 (tr) 1997-01-10 1998-01-09 Anti-CDL40 bilesiklerinin tedavi amaçli uygulama yöntemleri

Country Status (21)

Country Link
US (2) US20020071840A1 (tr)
EP (1) EP0966302B1 (tr)
JP (1) JP2001508450A (tr)
KR (2) KR20000070035A (tr)
CN (1) CN1248921A (tr)
AT (1) ATE356634T1 (tr)
AU (1) AU721697B2 (tr)
BR (1) BR9807471A (tr)
CA (1) CA2277223A1 (tr)
CZ (1) CZ244399A3 (tr)
DE (1) DE69837322T2 (tr)
EA (1) EA001426B1 (tr)
EE (1) EE9900275A (tr)
HK (1) HK1024424A1 (tr)
IL (1) IL130785A0 (tr)
IS (1) IS5101A (tr)
NO (1) NO993275L (tr)
NZ (1) NZ337073A (tr)
PL (1) PL193966B1 (tr)
TR (1) TR199902192T2 (tr)
WO (1) WO1998030241A1 (tr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474771A (en) 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US7070777B1 (en) 1991-11-15 2006-07-04 The Trustees Of Columbia University In The City Of New York Method for inhibiting inflammation with an antibody that binds the 5C8 protein
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
AU735592B2 (en) * 1997-05-17 2001-07-12 Biogen Idec Ma Inc. Use of a CD40:CD154 binding interruptor to prevent counter adaptive immune responses, particularly graft rejection
TR199903141T2 (tr) * 1997-06-20 2000-09-21 Biogen, Inc. Terapötik protein engelleyici sendrom için CD154 blokaj tedavisi.
CN1331602A (zh) * 1998-09-21 2002-01-16 遗传研究所有限公司 负调节针对医用蛋白的免疫反应的方法
EP1101495A4 (en) * 1999-06-01 2003-05-07 Eisai Co Ltd PREVENTIVE AGENTS AGAINST IDIOPATHIC THROMOBOCYTOPENIC PURPURA
GB9927757D0 (en) * 1999-11-25 2000-01-26 Kennedy Rheumatology Inst Treatment of autoimmune diseases
US20030170231A1 (en) * 2000-03-06 2003-09-11 Toshihiko Yamauchi Remedies and preventives for antiphospholipid antibody syndrome
WO2001079555A2 (en) 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
AU2001259691B2 (en) 2000-05-12 2006-02-16 Genzyme Corporation Modulators of TNF-alpha signaling
JP3785508B2 (ja) * 2002-04-15 2006-06-14 学校法人慶應義塾 遺伝子治療における免疫応答を解析できる実験モデルマウス
DK1562571T3 (da) * 2002-11-21 2011-12-05 Genzyme Corp Kombination af et diamidderivat og immunsuppressive midler til hæmning af transplantatafstødning
DK2367849T3 (en) 2008-12-05 2018-01-22 Als Therapy Development Inst METHOD OF TREATING NEURODEGENERATIVE DISEASES

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962406A (en) * 1991-10-25 1999-10-05 Immunex Corporation Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
US5981724A (en) * 1991-10-25 1999-11-09 Immunex Corporation DNA encoding CD40 ligand, a cytokine that binds CD40
US5961974A (en) * 1991-10-25 1999-10-05 Immunex Corporation Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
US5474771A (en) * 1991-11-15 1995-12-12 The Trustees Of Columbia University In The City Of New York Murine monoclonal antibody (5c8) recognizes a human glycoprotein on the surface of T-lymphocytes, compositions containing same
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5540926A (en) * 1992-09-04 1996-07-30 Bristol-Myers Squibb Company Soluble and its use in B cell stimulation
ZA946765B (en) * 1993-09-02 1996-02-15 Dartmouth College Methods of prolonged suppression of humoral immunity
JP2991499B2 (ja) * 1993-09-02 1999-12-20 トラスティーズ・オブ・ダートマス・カレッジ 抗ｇｐ３９抗体およびその用途
US5869049A (en) * 1993-09-02 1999-02-09 Trustees Of Dartmouth College Methods of inducing T cell unresponsiveness to bone marrow with gp39 antagonists
ES2134954T3 (es) * 1993-09-02 1999-10-16 Dartmouth College Procedimiento de supresion prolongada de la inmunidad humoral.
US5674492A (en) * 1993-12-23 1997-10-07 Immunex Corporation Method of preventing or treating disease characterized by neoplastic cells expressing CD40
US5683693A (en) * 1994-04-25 1997-11-04 Trustees Of Dartmouth College Method for inducing T cell unresponsiveness to a tissue or organ graft with anti-CD40 ligand antibody or soluble CD40
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5833987A (en) * 1995-06-07 1998-11-10 Trustees Of Dartmouth College Treatment of T cell mediated autoimmune disorders
US6001358A (en) * 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Also Published As

Publication number Publication date
US20050158314A1 (en) 2005-07-21
CA2277223A1 (en) 1998-07-16
DE69837322T2 (de) 2007-11-22
IS5101A (is) 1999-06-30
CN1248921A (zh) 2000-03-29
EE9900275A (et) 2000-02-15
CZ244399A3 (cs) 1999-10-13
US20020071840A1 (en) 2002-06-13
HK1024424A1 (en) 2000-10-13
EA001426B1 (ru) 2001-02-26
KR100632846B1 (ko) 2006-10-16
PL193966B1 (pl) 2007-04-30
PL334500A1 (en) 2000-02-28
JP2001508450A (ja) 2001-06-26
EP0966302B1 (en) 2007-03-14
ATE356634T1 (de) 2007-04-15
EA199900633A1 (ru) 2000-02-28
AU5735398A (en) 1998-08-03
AU721697B2 (en) 2000-07-13
WO1998030241A1 (en) 1998-07-16
NZ337073A (en) 2001-01-26
IL130785A0 (en) 2001-01-28
BR9807471A (pt) 2000-03-21
KR20000070035A (ko) 2000-11-25
DE69837322D1 (de) 2007-04-26
NO993275D0 (no) 1999-07-01
EP0966302A1 (en) 1999-12-29
KR20050088494A (ko) 2005-09-06
NO993275L (no) 1999-09-09

Similar Documents

Publication Publication Date Title
TR199902192T2 (tr) Anti-CDL40 bilesiklerinin tedavi amaçli uygulama yöntemleri
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69922914D1 (de) Stimulationssystem zur Behandlung von Erkrankungen bezüglich des Magenspeiseröhrenreflux
ES2143611T3 (es) Compuestos de peptidilo y su uso terapeutico como inhibidores de metaloproteinasas.
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
ATE303162T1 (de) Natrium kanalblocker zusammensetzungen und deren verwendung
DE60024660D1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
DE69616333D1 (de) Thip zur behandlung von schlafstörungen
ATE527022T1 (de) Verwendung von cyclooxygenase-2-inhibitoren zur behandlung und vorbeugung von tumoren, von tumor- abhängigen erkrankungen und kachexie
DE69526437T2 (de) Transdermal verabreichbare zubereitung zur behandlung von störungen des harnlassens
ATE253361T1 (de) Mittel zur gesteuerten freisetzung von paroxetin
FR2760369B1 (fr) Stimulateur cardiaque multisites pour le traitement des insuffisances cardiaques par stimulation
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69840752D1 (de) Verwendung von coumarine zur behandlung von lebererkrankungen und pankreaserkrankungen
ATE210447T1 (de) Verwendung von cck-b rezeptor antagonisten zur behandlung von schlafstörungen
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE69936994D1 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
NO994526D0 (no) FremgangsmÕte for stimulering av neural regenerering
DE69806062D1 (de) Kombinationstherapie zur behandlung von aids
ATE298244T1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf- erkrankungen
DE68908445T2 (de) Mittel zur Behandlung von Lebererkrankungen.
DE69813354T2 (de) Mittel zur Behandlung von Herzkrankheiten
NO20015572D0 (no) Fremgangsmåte til å identifisere terapeutiske forbindelser for behandling av leverlidelser
DE69807586T2 (de) Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen
DK1117421T3 (da) Hidtil ukendte fremgangsmåder til terapuetisk vaccination